Loading
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) Stock: price and insider trades · Canada
CA·Mcap CA$37.1M
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation): what insiders have been doing
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) is a listed company. Its insiders report their share dealings to SEDI. The last twelve months, up to 18 October 2026, brought 7 filings signed by 3 insiders.
The flow runs one way only: 2 insiders bought (2 purchases totalling €95k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 2 senior executives among the declarants. One trade stands out by size: a purchase of €79k from Aharon, Gilad, disclosed on 23 September 2026, or 0.35% of market capitalisation.
For context, the typical company on the same exchange (median of 2,121 companies) published 11 filings over the same period, against 7 filings here. Our records for Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) go back to 2026, with 2 purchases and no sales on the open market in total.
The most recent open-market purchase was published on 1 October 2026, 16 days ago. Typically, a trade is published a median of 2 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€95,183
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBrook Riggins1 buy
Gilad Aharon1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$0.53
Analyst consensus
Income statement
EBITDA-CA$7.4M
Net income-CA$7.4M0.0% margin
Valuation
P/Book5.5x
Beta0.61
Balance sheet & cash
Market capCA$37.1M
Total debtCA$461.9k
Free Cash Flow-CA$6M
Profitability & ownership
ROE-181.5%
ROA-87.2%
% insiders14.2%
% institutions0.0%
Last declaration on 1 October 2026
Declarations7 total
50,000 shares@ CA$0.520.076% mcap100.0% of flowCommon SharesTSXSEDI:4783390
Canonical exit: 28 Dec 2026 (T+90)
249,500 shares@ CA$0.510.35% mcap55.9% of flowCommon SharesTSXSEDI:4780719
Canonical exit: 21 Dec 2026 (T+90)
200,000 shares@ CA$0.500.28% mcap44.1% of flowOptionsTSXSEDI:4779607
OptionsTSXSEDI:4779606
Common SharesTSXSEDI:4766240
Common SharesTSXSEDI:4766233
150,000 shares@ CA$0.50100.0% of flowCommon SharesTSXSEDI:4726911
7 of 7 declarations
About Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)
Thiogenesis Therapeutics, Corp. is a biotechnology company focused on developing innovative treatments for serious diseases. Formerly known as Rozdil Capital Corporation, it is listed on the XTSE.
